• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在巴西(北里奥格兰德州圣贡萨洛-杜阿马兰特)的一个流行地区,使用FML-皂树素疫苗对犬类黑热病进行长期保护。

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).

作者信息

Borja-Cabrera G P, Correia Pontes N N, da Silva V O, Paraguai de Souza E, Santos W R, Gomes E M, Luz K G, Palatnik M, Palatnik de Sousa C B

机构信息

Instituto de Microbiologia, Prof. Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), CCS, Cidade Universitária, Ilha do Fundão, Caixa Postal 68040, CEP 21941-590, Brazil.

出版信息

Vaccine. 2002 Sep 10;20(27-28):3277-84. doi: 10.1016/s0264-410x(02)00294-3.

DOI:10.1016/s0264-410x(02)00294-3
PMID:12213397
Abstract

Naturally exposed dogs of an endemic area were vaccinated with the fucose mannose ligand (FML) antigen of Leishmania donovani in formulation with QuilA saponin. The 100% of vaccinees were seropositive to FML and showed intradermal reaction to L. donovani lysate, 2 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls along a 3.5 years period (ANOVA, P<0.0001). The 25% of the control animals (two dogs on the first year and six dogs on the fourth year, respectively) and 5% of the vaccinees (one dog during the fourth year) developed clinical and fatal disease until the end of experiment. This difference was significant (chi(2)=3.93, P<0.05). This means that 95% protection against kala-azar was achieved in vaccinees, after FML-QuilA vaccination (80% of vaccine efficacy (VE)). Leishmania infection was also confirmed, 3.5 years after vaccination, in saline controls that showed positive polymerase chain reaction (PCR) for Leishmania DNA and FML-serology with no intradermal reaction. Higher seropositivities and intradermal reactions with no Leishmanial DNA were detected in vaccinees. The FML-QuilA vaccine induced a significant, long lasting and strong protective effect against canine kala-azar in the field.

摘要

在流行地区自然暴露的犬只接种了与QuilA皂苷配制成制剂的杜氏利什曼原虫岩藻糖甘露糖配体(FML)抗原。接种疫苗2个月后,100%的接种者对FML呈血清阳性,且对杜氏利什曼原虫裂解物有皮内反应。在3.5年的时间里,接种者的吸光度值和皮内反应大小均显著高于对照组(方差分析,P<0.0001)。直到实验结束,25%的对照动物(第一年两只狗,第四年六只狗)和5%的接种者(第四年一只狗)出现了临床和致命疾病。这种差异具有统计学意义(χ²=3.93,P<0.05)。这意味着在接种FML - QuilA疫苗后,接种者对黑热病的保护率达到了95%(疫苗效力(VE)为80%)。在接种疫苗3.5年后,在生理盐水对照组中也证实了利什曼原虫感染,这些对照组的利什曼原虫DNA聚合酶链反应(PCR)呈阳性且FML血清学呈阳性,但无皮内反应。在接种者中检测到更高的血清阳性率和无利什曼原虫DNA的皮内反应。FML - QuilA疫苗在野外对犬黑热病诱导了显著、持久且强大的保护作用。

相似文献

1
Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).在巴西(北里奥格兰德州圣贡萨洛-杜阿马兰特)的一个流行地区,使用FML-皂树素疫苗对犬类黑热病进行长期保护。
Vaccine. 2002 Sep 10;20(27-28):3277-84. doi: 10.1016/s0264-410x(02)00294-3.
2
A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).
Vaccine. 2000 Dec 8;19(9-10):1082-92. doi: 10.1016/s0264-410x(00)00339-x.
3
Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.使用FML疫苗对犬内脏利什曼病进行有效的免疫治疗。
Vaccine. 2004 Jun 2;22(17-18):2234-43. doi: 10.1016/j.vaccine.2003.11.039.
4
Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.利什曼疫苗可阻断犬内脏利什曼病的传播:接种疫苗后暴露于该病环境的犬只血液、皮肤和淋巴结中无利什曼原虫。
Vaccine. 2005 Sep 23;23(40):4805-10. doi: 10.1016/j.vaccine.2005.05.011.
5
Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.在法国流行地区使用LiESAp-MDP疫苗对犬内脏利什曼病进行长期保护:双盲随机疗效现场试验。
Vaccine. 2007 May 22;25(21):4223-34. doi: 10.1016/j.vaccine.2007.02.083. Epub 2007 Mar 15.
6
Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.皂树混合酰化和去酰化皂苷作为抗内脏利什曼病FML疫苗的佐剂
Vaccine. 2006 May 1;24(18):3909-20. doi: 10.1016/j.vaccine.2006.02.034. Epub 2006 Mar 2.
7
Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.用于抗小鼠内脏利什曼病的FML疫苗制剂中的皂苷、白细胞介素12和卡介苗佐剂。
Vaccine. 2002 Nov 22;21(1-2):30-43. doi: 10.1016/s0264-410x(02)00444-9.
8
Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
Vaccine. 2001 Apr 30;19(23-24):3104-15. doi: 10.1016/s0264-410x(01)00031-7.
9
Cytokine Profile of Leishmania Infantum Fucose-Mannose Ligand in Vaccinated Dogs in the Northwest of Iran.伊朗西北部接种疫苗犬体内婴儿利什曼原虫岩藻糖-甘露糖配体的细胞因子谱
Iran J Immunol. 2017 Dec;14(4):293-305.
10
Canine Leishmania vaccines: still a long way to go.犬利什曼原虫疫苗:仍有很长的路要走。
Vet Parasitol. 2015 Feb 28;208(1-2):94-100. doi: 10.1016/j.vetpar.2015.01.003. Epub 2015 Jan 15.

引用本文的文献

1
Extracellular Vesicles Derived from Trypanosomatids: The Key to Decoding Host-Parasite Communication.源自锥虫的细胞外囊泡:解码宿主-寄生虫通讯的关键
Int J Mol Sci. 2025 May 1;26(9):4302. doi: 10.3390/ijms26094302.
2
Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis.针对人类内脏利什曼病的高度保守、HLA多态性T细胞多表位疫苗的设计与开发。
Front Immunol. 2025 Mar 31;16:1540537. doi: 10.3389/fimmu.2025.1540537. eCollection 2025.
3
Vaccination in Leishmaniasis: A Review Article.
《利什曼病疫苗接种:综述文章》。
Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35.
4
FML/QuilA-Vaccinated Dogs Naturally Infected with : Serum Cytokines, Clinicopathological Profile, and Parasitological Parameters.FML/QuilA 疫苗接种犬自然感染:血清细胞因子、临床病理概况和寄生虫学参数。
Biomed Res Int. 2021 Oct 5;2021:3192960. doi: 10.1155/2021/3192960. eCollection 2021.
5
Phase I and II Clinical Trial Comparing the LBSap, Leishmune, and Leish-Tec Vaccines against Canine Visceral Leishmaniasis.比较LBSap、利什曼疫苗和Leish-Tec疫苗预防犬内脏利什曼病的I期和II期临床试验。
Vaccines (Basel). 2020 Nov 17;8(4):690. doi: 10.3390/vaccines8040690.
6
The Delay in the Licensing of Protozoal Vaccines: A Comparative History.原生动物疫苗的许可延迟:比较历史。
Front Immunol. 2020 Mar 6;11:204. doi: 10.3389/fimmu.2020.00204. eCollection 2020.
7
Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis.基于肽的疫苗成功诱导出针对犬内脏利什曼病的保护性免疫。
NPJ Vaccines. 2019 Nov 29;4:49. doi: 10.1038/s41541-019-0144-2. eCollection 2019.
8
Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis.犬内脏利什曼病疫苗诱导免疫的评估
Front Vet Sci. 2019 Jun 4;6:168. doi: 10.3389/fvets.2019.00168. eCollection 2019.
9
Nucleoside Hydrolase NH 36: A Vital Enzyme for the Genus in the Development of T-Cell Epitope Cross-Protective Vaccines.核苷水解酶 NH36:T 细胞表位交叉保护疫苗研发中属水平至关重要的酶。
Front Immunol. 2019 Apr 16;10:813. doi: 10.3389/fimmu.2019.00813. eCollection 2019.
10
Saponins from and : Particular Chemical Characteristics and Biological Activities.和:特定的化学特征和生物活性的皂苷。
Molecules. 2019 Jan 4;24(1):171. doi: 10.3390/molecules24010171.